Successful treatment of hepatitis E virus-associated cryoglobulinemic membranoproliferative glomerulonephritis with ribavirin.

Abstract

Hepatitis E virus genotype-3 (HEV3) infection can cause chronic hepatitis in immunosuppressed patients and induce extra-hepatic manifestations, such as neurological symptoms, kidney injuries, and immune-mediated thrombocytopenia. Very few cases of HEV-induced kidney manifestations have been reported. Herein, we report, for the first time, a case of de novo membranoproliferative glomerulonephritis that occurred in a kidney transplant patient who developed a chronic HEV3 infection, which was successfully treated with ribavirin.

• Authors: A Del Bello, C Guilbeau-Frugier, A-G Josse, L Rostaing, J Izopet, N Kamar
• Journal: Transplant infectious disease : an official journal of the Transplantation Society (Transpl Infect Dis) Vol. 17 Issue 2 Pg. 279-83 (Apr 2015) ISSN: 1399-3062 [Electronic] Denmark
• PMID: 25708383 (Publication Type: Case Reports, Journal Article)
• Copyright: © 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Chemical References

• Antiviral Agents
• Immunosuppressive Agents
• Ribavirin

Topics

• Antiviral Agents (therapeutic use)
• Cryoglobulinemia (drug therapy, etiology, virology)
• Glomerulonephritis, Membranoproliferative (drug therapy, etiology, virology)
• Graft Rejection (prevention & control)
• Hepatitis E (drug therapy)
• Hepatitis E virus
• Humans
• Immunocompromised Host
• Immunosuppressive Agents (adverse effects)
• Kidney Transplantation
• Male
• Middle Aged
• Nephritis, Hereditary (surgery)
• Ribavirin (therapeutic use)
• Transplant Recipients
• Treatment Outcome